Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique

被引:6
作者
Barabas, Arpad Zsigmond [1 ]
Cole, Chad Douglas [2 ]
Barabas, Arpad David [1 ]
Graeff, Richard Milton [3 ]
Lafreniere, Rene [1 ]
Weir, Donald Mackay [4 ]
机构
[1] Univ Calgary, Dept Surg, Calgary, AB T2N 4N1, Canada
[2] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA
[3] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA
[4] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland
关键词
Autoimmune anomalies; Prophylactic; Therapeutic; Modified vaccination technique; Tolerance to self; PROGRESSIVE HEYMANN NEPHRITIS; PATHOGENIC AUTOANTIBODY RESPONSE; DOWN-REGULATION; POLYREACTIVE ANTIBODIES; KIDNEY-DISEASE; ORAL TOLERANCE; HUMAN CD38; ANTIGEN; VACCINES; IMMUNOTHERAPY;
D O I
10.1016/j.autrev.2009.01.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Our research group has developed a new vaccination technique in experimental animals that has the potential of correcting autoimmune anomalies in humans such as autoimmune disorders, cancer, and chronic infections, both prophylactically and therapeutically. The vaccination method is called Modified Vaccination Technique (MVT). The MVT necessitates the introduction of a purified target antigen (ag) and a specific antibody (ab) against the target ag in the form of immune complex (IC) to evoke the desired immune response outcome by ab information transfer in the injected recipient. The injected IC produces the same class of ab in the host, with the same specificity against the target ag, as resides in the inoculum. The MVT promises to provide a means of upregulating beneficial immune events and downregulating undesirable immune responses in individuals, thereby re-establishing normalcy/tolerance to self. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:552 / 557
页数:6
相关论文
共 40 条
[1]
AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
[2]
Barabas AZ, 2007, BIOL-TARGETS THER, V1, P59
[3]
Barabas AZ, 2008, IDRUGS, V11, P111
[4]
Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Barabas, AN ;
Lafreniere, R .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2006, 13 (01) :17-24
[5]
Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
PATHOLOGY INTERNATIONAL, 2006, 56 (04) :181-190
[6]
Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease [J].
Barabas, AZ ;
Lafreniere, R .
AUTOIMMUNITY REVIEWS, 2005, 4 (08) :565-570
[7]
Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (06) :321-334
[8]
Production of Heymann nephritis by a chemically modified renal antigen [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (05) :277-285
[9]
Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Cowan, JM ;
Yoon, CS ;
Waisman, DM ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (04) :201-212
[10]
BARABAS AZ, 1969, CLIN EXP IMMUNOL, V4, P345